Transforming growth factor‐β1 protects against white matter injury and reactive astrogliosis via the p38 MAPK pathway in rodent demyelinating model
Yi Xie,Xuejiao Chen,Xinyue Wang,Shuai Liu,Simiao Chen,Zhiyuan Yu,Wei Wang
DOI: https://doi.org/10.1111/jnc.16037
2024-01-07
Journal of Neurochemistry
Abstract:Brain stereotactic injection of LPC leads to local robust demyelination and reactive astrogliosis in the corpus callosum of mice. Supplementary TGF‐β1 binds to its receptor TGF‐βRI/II and then promotes the translocation of downstream molecule Smad3 into the nuclei. As a transcription factor, activated Smad3 regulates the expression of corresponding genes (such as MAG and MBP) to exert subsequent functions. Specifically, activation of TGF‐β1 pathway accelerates the maturation and migration processes of OLs, and restores the reactive astrogliosis probably through regulating the p38 MAPK signal pathway. Ultimately, supplement of TGF‐β1 significantly attenuates the demyelinating lesion and behavioral disorders in LPC modeling mice. In central nervous system (CNS), demyelination is a pathological process featured with a loss of myelin sheaths around axons, which is responsible for the diseases of multiple sclerosis, neuromyelitis optica, and so on. Transforming growth factor‐beta1 (TGF‐β1) is a multifunctional cytokine participating in abundant physiological and pathological processes in CNS. However, the effects of TGF‐β1 on CNS demyelinating disease and its underlying mechanisms are controversial and not well understood. Herein, we evaluated the protective potential of TGF‐β1 in a rodent demyelinating model established by lysophosphatidylcholine (LPC) injection. It was identified that supplement of TGF‐β1 evidently rescued the cognitive deficit and motor dysfunction in LPC modeling mice assessed by novel object recognition and balance beam behavioral tests. Besides, quantified by luxol fast blue staining, immunofluorescence, and western blot, administration of TGF‐β1 was found to significantly ameliorate the demyelinating lesion and reactive astrogliosis by suppressing p38 MAPK pathway. Mechanistically, the results of in vitro experiments indicated that treatment of TGF‐β1 could directly promote the differentiation and migration of cultured oligodendrocytes. Our study revealed that modulating TGF‐β1 activity might serve as a promising and innovative therapeutic strategy in CNS demyelinating diseases.
biochemistry & molecular biology,neurosciences